Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes.  This product will be manufactured under cGMP conditions as a kit for radio-labeling for use in clinical trials. Terms of the manufacturing agreement were not disclosed.

"This project will allow us to utilize our extensive experience and expertise in bio-conjugation technologies that we have honed over the last few years" said Muctarr Sesay, Ph. D., Vice President of Process Development at Goodwin Biotechnology. "We have had great history in developing and producing antibody-drug conjugates for diagnostic imaging and therapeutics, and this project is already underway with excellent progress.

"We have recently seen a strong interest in bio-conjugations from the biopharmaceutical industry to develop improved imaging and therapeutic biologic compounds," commented SooYoung Lee, Ph.D. Sr. Vice President of Operations. "Along with bio-conjugations, monoclonal antibody and recombinant therapeutic protein process development and cGMP manufacturing have become Goodwin's core competencies." "Most of our customers are looking for one stop shop type of CMO services that will provide development, bulk production, characterization and fill/finish at one location" said Dr. Lee.. "This client realizes the value in these combined services, and we expect a long-term relationship to grow out of this initial project with them. I believe they have a partner in Goodwin that will provide the excellent technology, time and cost management that is difficult to find".